• 10/07/2024,

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241007_PR_shares_votingrights_September2024.pdf
  • 09/11/2024, Sophia Antipolis, France

    Median Technologies to attend and present at the ESMO Congress 2024, being held in Barcelona, Spain, from Sept 13-17, 2024

    Median iCRO and eyonis™ teams will be present to welcome interested parties at Booth #525, Hall 3, from September 13-16 (exhibition dates). The Company will share the most recent advances for iCRO AI-powered clinical trial imaging services as well as latest developments for eyonis™ LCS SaMD. Median eyonis™ team will present a peer-reviewed poster presentation of the full positive results of the independent verification study for Median proprietary SaMD eyonis™ LCS.
    Read more Download 20240911_PR_ESMO2024_final_EN.pdf
  • 09/06/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20240906_PR_shares_votingrights_August2024.pdf
  • 09/04/2024, Sophia Antipolis, France

    Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer (San Diego, CA, USA, from September 7-10, 2024)

    The Company will be sharing information on its proprietary AI/ML-powered SaMD, eyonis™ LCS, including recently announced data from the pivotal REALITY study, at Booth #2601 during the 2024 World Conference on Lung Cancer, being held in San Diego, CA, USA, from September 7-10, 2024. The WCLC, the premier world conference on lung cancer, is organized by the International Association for the Study of Lung Cancer, a global multidisciplinary association dedicated to eradication of all forms of lung cancers.
    Read more Download 20240904_PR_WCLC2024_EN.pdf
  • 09/02/2024, Sophia Antipolis, France

    Median Technologies to host two webcasts on September 5, 2024 – “eyonis™ LCS: New Horizons in Fighting Lung Cancer”

    Following the recent release of results of the eyonis™ LCS REALITY study, Fredrik Brag, CEO and Founder of Median Technologies, will offer further insights into the significance of eyonis™ LCS and discuss the next steps for Median’s novel Software as a Medical Device.
    Read more Download 20240902_PR_Webcast_EN.pdf
  • 08/29/2024, Sophia Antipolis, France

    Median Technologies announces pivotal REALITY study of its eyonis™ LCS lung cancer diagnostic met all primary and secondary endpoints

    Median Technologies announces today that eyonis™ LCS, its proprietary AI/ML-powered Software as Medical Device for lung cancer screening, met the primary and all secondary endpoints in REALITY, the first of two pivotal studies required for marketing authorizations in U.S. and Europe.
    Read more Download 20240829_PR_REALITY_EN_final.pdf
  • 08/08/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of July 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of July 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20240808_PR_shares_votingrights_July2024.pdf
  • 08/06/2024, Sophia Antipolis, France

    Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery

    The partnership’s aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab’s unique AI capabilities. The company is a Top 10 global oncology pharmaceutical company. Imaging Lab is a division of iCRO, launched in 2022, that applies Artificial Intelligence (AI), Machine Learning (ML), radiomics and data mining, to extract insights from clinical trial images.
    Read more Download 20240806_PR_ImagingLab_Top10_EN_final.pdf
  • 07/18/2024, Sophia Antipolis, France

    Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August

    Median Technologies reports today its business indicators for the first half of 2024, provide an update on recent iCRO successful business achievements.
    Read more Download 20240718_PR_H12024_EN_FINAL.pdf
  • 07/11/2024, Sophia Antipolis, France

    Financial communication schedule for the second half of 2024

    Median Technologies announces the publication date for its 2024 half year results and Q3, 2024 business activity: October 214, 2024 after close of trading
    Read more Download 20240711_PR_H1fincomm2024_EN.pdf
    • 1 … 39